KYNB

#4548
Kyntra Bio, Inc. Common Stock
7.23 USD
-1.90%
Sector:
Básica: USD
Divisa de beneficio: USD
Rango diario
7.23
7.23
Rango anual
6.32
9.70
Cambio diario
-1.90%
Variación mensual
+1.12%
Variación en los últimos 6 meses
-23.97%
Cambio anual
-23.97%
Cierres anteriores
7.37
Abrir
7.23
Bid
Ask
Mínimo
7.23
High
7.23
Volumen
3
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Kyntra Bio Inc

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.